Filter results
You can narrow down the results using the filters
Audience
Topics
Our work
Diseases
11458 results
-
59:47Support at Home program questions and answers session – In-home aged care providers – Video
This targeted questions and answers session provided an opportunity to ask us questions about the Support at Home program and transition. -
Changes to vaping in Australia from 1 October 2024 – fact sheet for parents and carers
This fact sheet contains information for parents and carers on the changes to vaping in Australia. -
Changes to vaping in Australia from 1 October 2024 – Fact sheet for people who vape
This fact sheet contains information on the changes to vaping in Australia. -
16:06NDIS Bill overview – Auslan
This video provides a summary of the key changes in the National Disability Insurance Scheme Amendment (Getting the NDIS Back on Track No. 1) Act 2024 (the Amendment Act). -
Sharing My Aged Care support plans to My Health Record resources
Resources about the ability to share My Aged Care support plans that are created or updated from 9 December with My Health Record, which enables health professionals to understand their patients’ aged care needs and to make quicker and more informed decisions. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break. -
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break. -
Life Saving Drugs Program – Gaucher disease (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1). -
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease. -
Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II. -
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA. -
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI. -
Life Saving Drugs Program – Gaucher disease (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Late-Infantile Onset Batten disease (CLN2 disease) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Pompe disease – Patient test results spreadsheets
Treating physicians use the relevant spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.